文献速递肺结节与肺癌

赛沃替尼一线治疗中国METex14突变晚期NSCLC的3b期验证研究

Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study.
PubMed 文献 · Lancet Respir Med · 2024-09-10

这项在中国48家医院开展的单臂、多队列、开放标签3b期研究纳入87例未接受过系统抗肿瘤治疗的局部晚期或转移性METex14突变NSCLC患者,给予赛沃替尼每日一次口服(体重≥50kg者600mg,<50kg者400mg)。独立评审委员会评估的客观缓解率为62%(95%CI 51-72),研究者评估为60%(49-70),治疗相关不良事件发生率为98%,最常见为外周水肿(62%)。

要点

  • 初治METex14突变晚期NSCLC患者接受赛沃替尼,IRC评估ORR达62%。
  • 治疗相关不良事件发生率98%,最常见为外周水肿(62%)。
  • 2例治疗相关不良事件导致死亡(心力衰竭1例、原因不明1例)。

核心结论

  • 赛沃替尼在初治晚期或转移性METex14突变NSCLC患者中显示出可控的毒性和有前景的疗效。

研究设计与样本

  • 单臂、多队列、多中心、开放标签3b期验证研究,在中国48家医院开展。
  • 纳入87例未接受过系统抗肿瘤治疗的成人(≥18岁)局部晚期或转移性METex14突变NSCLC患者。
  • 体重≥50kg者接受赛沃替尼600mg每日一次,体重<50kg者接受400mg每日一次,21天为一个周期。
  • 主要终点为独立评审委员会(IRC)按RECIST v1.1评估的客观缓解率。
  • 全分析集为至少接受一剂研究药物的所有患者,用于疗效、基线和安全性评估。

主要发现

  • 全分析集中,IRC评估的客观缓解率为62%(95%CI 51-72),研究者评估为60%(49-70),一致性率为84%。
  • 治疗相关不良事件发生于85例(98%)患者,最常见为外周水肿54例(62%)。
  • 2例治疗相关不良事件导致死亡(心力衰竭1例、原因不明1例)。

临床怎么用

  • 对于初治的METex14突变晚期NSCLC患者,赛沃替尼可作为治疗选择之一,需关注外周水肿等不良事件。

局限性

  • 单臂设计,无对照组,疗效结论需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Savolitinib has been approved in China for advanced or metastatic non-small-cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping alterations in previously treated patients and those unable to receive platinum-based chemotherapy. We report results from a treatment-naive cohort of a phase 3b study that was designed to evaluate the efficacy and safety of savolitinib in locally advanced or metastatic METex14-mutated NSCLC. METHODS: This single-arm, multicohort, multicentre, open-label, phase 3b study was done at 48 hospitals in China in adult (≥18 years) patients with locally advanced or metastatic METex14-mutated NSCLC who had not received previous systemic antitumour therapy. Patients with a bodyweight of 50 kg or more and those with a bodyweight of less than 50 kg received savolitinib once daily at 600 mg or 400 mg, respectively, in 21-day cycles. The primary endpoint was objective response rate assessed by independent review committee (IRC) per Response Evaluation Criteria in Solid Tumours, version 1.1. The full analysis set comprised all patients who received at least one dose of study medication, which was used to assess the efficacy endpoints and baseline and safety data. This study is registered with ClinicalTrials.gov (NCT04923945) and is closed to accrual. FINDINGS: Between Aug 31, 2021, and Oct 20, 2023, 125 treatment-naive patients were assessed for eligibility, of whom 87 were enrolled and received savolitinib. The median age of patients was 70·0 years (IQR 65·2-75·8) and 51 (59%) of 87 patients were male and 36 (41%) were female. In the full analysis set, the IRC-assessed objective response rate was 62% (95% CI 51-72) and the investigator-assessed objective response rate was 60% (49-70), showing a high concordance rate (84%). Treatment-related adverse events were reported in 85 (98%) of 87 patients, with peripheral oedema (54 [62%]) being the most common. Two of these treatment-related adverse events led to death (cardiac failure n=1, unknown reasons n=1). INTERPRETATION: Savolitinib showed manageable toxicity and promising efficacy in treatment-naive patients with advanced or metastatic METex14-mutated NSCLC. FUNDING: HUTCHMED and AstraZeneca.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Yu Y, Guo Q, Zhang Y, et al. Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study. Lancet Respir Med. 2024. PMID: 39270695. doi:10.1016/S2213-2600(24)00211-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。